Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 3 Multiple Myeloma 2 Melanoma 2 Lung Neoplasms 2 Gastrointestinal Neoplasms 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Thoracic Neoplasms 1 Solid Tumors 1 Skin Neoplasms 1 Sarcoma 1 Respiratory Tract Neoplasms 1 Respiratory Tract Diseases 1 Pancreatic Neoplasms 1 Pancreatic Adenocarcinoma 1 Ovarian Neoplasms 1 Noonan Syndrome 1 Neoplasms, Squamous Cell 1 Neoplasms by Site 1 Neoplasms 1 Lung Diseases 1 Esophageal Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Squamous Cell 1 Bronchial Neoplasms 1 Breast Neoplasms 1 Advanced or Metastatic Solid Tumors 1

Interventions

pembrolizumab 4 Injections 3 Nivolumab 2 Docetaxel 2 taxane 1 pazopanib 1 palbociclib 1 lenvatinib 1 demplatin pegraglumer 1 cobimetinib 1 birinapant 1 Topotecan 1 Tablets 1 ODM-207 1 Infusions, Intravenous 1 HLA-A*24:02 antigen 1 Gemcitabine 1 E-3810 1 CB-839 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Solid Tumors × cobimetinib × Clear all

NCT02639546 2022-09-16

iMATRIXcobi

Hoffmann-La Roche

Phase 1/2 Completed

56 enrolled 31 charts

Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡